Oxcarbazepine (All indications)

Low Apgar score (< 7) (at 5 min)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9042
R30868		 Bank (Oxcarbazepine) (Mixed indications), 2017 Apgar < 7 at 5 minutes during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No 10.14 [0.17;594.47] C 0/4   0/36 0 4
ref
S9036
R30805		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.38 [0.06;2.29] C
excluded (control group) 		2/230   3/132 5 230
ref
S9037
R30817		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 0.72 [0.18;2.91]
excluded (control group) 		2/230   3,014/269,151 3,016 230
ref
S9038
R30829		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 5-min Apgar <7 3rd trimester population based cohort retrospective unexposed, sick Adjustment: Yes 0.70 [0.14;3.49] 2/230   3/652 5 230
ref
Total 2 studies 1.35 [0.14;12.85] 5 234
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bank (Oxcarbazepine) (Mixed indications), 2017Bank, 2017 1 10.14[0.17; 594.47]0425%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 2 0.70[0.14; 3.49]523075%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 30% 1.35[0.14; 12.85]52340.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Mixed indications; 2: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.35[0.14; 12.85]523430%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.70[0.14; 3.49]5230 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 exposed to other treatment, sickexposed to other treatment, sick 10.14[0.17; 594.47]-4 -NABank (Oxcarbazepine) (Mixed indications), 2017 1 Tags Adjustment   - No  - No 10.14[0.17; 594.47]-4 -NABank (Oxcarbazepine) (Mixed indications), 2017 1   - Yes  - Yes 0.70[0.14; 3.49]5230 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 All studiesAll studies 1.35[0.14; 12.85]523430%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 20.250.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9036, 9037

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.72[0.18; 2.89]3,016230 -NAArtama (Oxcarbazepine) (Controls unexposed, disease free), 2013 1 unexposed, sick controlsunexposed, sick controls 0.70[0.14; 3.49]5230 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.15[0.05; 24.54]523452%NABank (Oxcarbazepine) (Mixed indications), 2017 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 20.510.01.0